Loading...
•
Sep 30, 2022
Heron Therapeutics Q3 2022 Earnings Report
Heron Therapeutics reported net product sales increase driven by oncology care franchise and ZYNRELEF, with APONVIE approved by the FDA.
Key Takeaways
Heron Therapeutics announced its Q3 2022 financial results, with net product sales of $26.6 million, an increase compared to $23.2 million for the same period in 2021. The company's net loss was $41.9 million, or $0.38 per share. The FDA approved APONVIE, and the company plans a U.S. launch in Q1 2023. ZYNRELEF unit demand grew 18% over the prior quarter, and oncology care franchise net product sales grew 13% over the prior year.
APONVIE was approved by the FDA, with a U.S. launch planned for Q1 2023.
ZYNRELEF unit demand grew 18% over the prior quarter in Q3 2022.
Oncology Care Franchise net product sales grew 13% over the prior year in Q3 2022.
A $75 million private placement was completed to strengthen the balance sheet.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.comZYNRELEF Revenue
CapyFin.com Forward Guidance
Heron expects fourth quarter 2022 ZYNRELEF net product sales to increase in the range of 30% to 40% over the prior quarter and full-year 2022 net product sales for the oncology care franchise of $93 million to $95 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income